Special: Bioprocessing

In this Issue:

Pharma companies increasingly rely on the know-how of contract organisations across the entire bioprocessing value chain: from DoE, QbD over process development to customized up- & downstream processing, polishing and filling the vials. What’s the most appropriate technology to efficiently produce complex novel formats such as ADCs, recombinant proteins, antibody conjugates, cancer immune or gene therapies or even biosimilars? Find the answer to what is the most economic cell line, equipment, engineering company, medium, as well as up- and downstream process in this EUROBIOTECH special report.

Marketing Contacts

Christian Böhm
Tel: +49-30-264921-49 

Oliver Schnell
Tel: +49-30-264921-45

Editorial Contact

Thomas Gabrielczyk
Tel: +49-30-264921-50